Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 12:9:135.
doi: 10.1186/1748-717X-9-135.

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Karel Decaestecker, Gert De Meerleer, Bieke Lambert, Louke Delrue, Valérie Fonteyne, Tom Claeys, Filip De Vos, Wouter Huysse, Arne Hautekiet, Gaethan Maes, Piet Ost  1
Affiliations

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Karel Decaestecker et al. Radiat Oncol. .

Abstract

Purpose: To assess the outcome of prostate cancer (PCa) patients diagnosed with oligometastatic disease at recurrence and treated with stereotactic body radiotherapy (SBRT).

Methods: Non-castrate patients with up to 3 synchronous metastases (bone and/or lymph nodes) diagnosed on positron emission tomography - computed tomography, following biochemical recurrence after local curative treatment, were treated with (repeated) SBRT to a dose of 50 Gy in 10 fractions or 30 Gy in 3 fractions. Androgen deprivation therapy-free survival (ADT-FS) defined as the time interval between the first day of SBRT and the initiation of ADT was the primary endpoint. ADT was initiated if more than 3 metastases were detected during follow-up even when patients were still asymptomatic. Secondary endpoints were local control, progression free survival (PFS) and toxicity. Toxicity was scored using the Common Terminology Criteria for Adverse Events.

Results: With a median follow-up from time of SBRT of 2 years, we treated 50 patients with 70 metastatic lesions with a local control rate of 100%. The primary involved metastatic sites were lymph nodes (54%), bone (44%), and viscera (2%). The median PFS was 19 mo (95% CI: 13-25 mo) with 75% of recurring patients having ≤3 metastases. A 2nd and 3rd course of SBRT was delivered in 19 and 6 patients respectively. This results in a median ADT-FS of 25 months (20-30 mo). On univariate analysis, only a short PSA doubling time was a significant predictor for both PFS (HR: 0.90, 95% CI: 0.82 - 0.99) and ADT-FS (HR: 0.83; 95% CI: 0.71 - 0.97). Ten patients (20%) developed toxicity following treatment, which was classified as grade I in 7 and grade II in 3 patients.

Conclusion: Repeated SBRT for oligometastatic prostate cancer postpones palliative androgen deprivation therapy with 2 years without grade III toxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic overview of relapse pattern of oligometastic prostate cancer recurrence following stereotactic body radiotherapy.
Figure 2
Figure 2
Probability of progression-free survival (a) and androgen deprivation therapy-free survival (b).
Figure 3
Figure 3
Pattern of relapse of pelvic lymph node (a) and bone metastases (b).
Figure 4
Figure 4
Probability of progression-free survival (a) and androgen deprivation therapy-free survival (b) stratified according to PSA doubling time ≤ 3mo compared to > 3 mo.
See this image and copyright information in PMC

References

    1. Palmbos PL, Hussain M. Non-castrate metastatic prostate cancer: have the treatment options changed? Semin Oncol. 2013;40:337–346. doi: 10.1053/j.seminoncol.2013.04.007. - DOI - PubMed
    1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–479. doi: 10.1016/j.eururo.2013.11.002. - DOI - PubMed
    1. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010;57:49–59. doi: 10.1016/j.eururo.2009.07.049. - DOI - PubMed
    1. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115:2388–2399. doi: 10.1002/cncr.24283. - DOI - PubMed
    1. Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, Eisenberger MA, Antonarakis ES. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Annals of Oncol. 2013;24:2881–2886. doi: 10.1093/annonc/mdt335. - DOI - PMC - PubMed

MeSH terms